Cost-Utility Analysis of the Inhaled Steroids Available in a Developing Country for the Management of Pediatric Patients with Persistent Asthma

References

• Centers for Disease Control and Prevention (CDC). Vital signs: Asthma prevalence, disease characteristics, and self-management education-United States, 2001–2009. MMWR Morb Mortal Wkly Rep 2011; 60:547–552.
   PubMedGoogle Scholar
• Dennis RJ, Caraballo L, García E, Rojas MX, Rondon MA, Pérez A, Aristizabal G, Peñaranda A, Barragan AM, Ahumada V, Jimenez S. Prevalence of asthma and other allergic conditions in Colombia 2009–2010: A cross-sectional study. BMC Pulm Med 2012; 13:12–17.
   Google Scholar
• Garcia E, Aristizabal G, Vasquez C, Rodriguez-Martinez CE, Sarmiento OL, Satizabal CL. Prevalence and factors associated with current asthma symptoms in school children aged 6–7 and 13–14 years old in Bogota, Colombia. Pediatr Allergy Immunol 2008; 19:307–314.
   PubMed Web of Science ®Google Scholar
• GINA Report. Global Strategy for asthma management and prevention, global initiative for asthma. 2011. Available at: http://www.ginasthma.org. Accessed September 17, 2012.
   Google Scholar
• Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmaeconomics 2006; 24:695–708.
   PubMed Web of Science ®Google Scholar
• Tina Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first- line controller therapies for persistent asthma. Pharmacoeconomics 2007; 25:577–590.
   PubMed Web of Science ®Google Scholar
• Price MJ, Briggs AH. Development of an economic model to assess the cost-effectiveness of asthma management strategies. Pharmaeconomics 2002; 20:183–194.
   PubMed Web of Science ®Google Scholar
• O’Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22:815–825.
   PubMed Web of Science ®Google Scholar
• Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmaeconomics 2002; 20:909–918.
   PubMed Web of Science ®Google Scholar
• Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100μg vs. fluticasone propionate 100μg in adults and adolescents with astma. III: Results. Pharmaeconomics 1999; 16(Suppl 2):15–21.
   Web of Science ®Google Scholar
• Stempel DA, Stanford RH, Thwaites R, Price MJ. Cost-efficacy comparison of inhaled fluticasone propionate ice MJ and budesonide in the treatment of asthma. Clin Ther 2000; 22:1562–1574.
   PubMed Web of Science ®Google Scholar
• Wang L, Hollenbeak CS, Mauger DT, Zeiger RS, Paul IM, Sorkness CA, Lemanske RFJr Martinez FD, Strunk RC, Szefler SJ, Taussig LM. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the pediatric asthma controller trial. J Allergy Clin Immunol 2011; 127:161–166.
   PubMed Web of Science ®Google Scholar
• Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994; 149:S69–S76.
   PubMed Web of Science ®Google Scholar
• Rubio-Terrés C, Echevarría A. Modelos de Markov: Una herramienta útil para el análisis farmacoeconómico. Pharmacoeconomics – Spanish Reasearch Articles 2006; 3:71–78.
   Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998; 13:397–409.
   PubMed Web of Science ®Google Scholar
• Mallol J, Aguirre V. Once versus twice daily budesonide metered-dose inhaler in children with mild to moderate asthma: Effect on symptoms and bronchial responsiveness. Allergol et Immunopathol 2007; 35:25–31.
   PubMed Web of Science ®Google Scholar
• Johasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000; 83:330–333.
   PubMed Web of Science ®Google Scholar
• Phillips K, Oborne J, Lewis S. Harrison TW, Tattersfield AE Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax 2004; 59:26–30.
   PubMed Web of Science ®Google Scholar
• Hoekx JC, Hedlin G, Pedersen W. Sorva R, Hollingworth K, Efthimiou J Fluticasone propionate compared with budesonide: A double-blind trial in asthmatic children using powder devices at a dosage of 400 μg/day. Eur Respir J 1996; 9:2263–2272.
   PubMed Web of Science ®Google Scholar
• Verberne AA, Frost C, Roorda RJ. van der Laag H, Kerrebijn KF One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997; 156:688–695.
   PubMed Web of Science ®Google Scholar
• Connett GJ, Warde C, Wooler E. Lenney W Use of budesonide in severe asthmatics aged 1–3 years. Arch Dis Child 1993; 69:351–355.
   PubMed Web of Science ®Google Scholar
• Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2 to 5 year-old asthmatic children. Am J Respir Crit Care Med 2000; 162:1500–1506.
   PubMed Web of Science ®Google Scholar
• Lönnkvist K, Hellman C, Lundahl J, Halldén G, Hedlin G. Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: Impact of budesonide treatment and withdrawal. J Allergy Clin Immunol 2001; 107:812–817.
   PubMed Web of Science ®Google Scholar
• Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once-daily ciclesonide in children: Efficacy and safety in asthma. J Pediatr 2006; 148:377–381.
   PubMed Web of Science ®Google Scholar
• Katz Y, Lebas FX, Medley HV, Robson R. Fluticasone propionate 50mcg BID versus 100mcg BID in the treatment of children with persistent asthma. Clin Ther 1998; 20:424–437.
   PubMed Web of Science ®Google Scholar
• Gleeson JGA, Price JF. Controlled trial of budesonide given by the Nebuhaler in preschool children with asthma. BMJ 1988; 297:163–166.
   PubMed Web of Science ®Google Scholar
• Boner AL, Piacentini GL, Bonizzato C, Dattoli V, Sette L. Effect of inhaled beclomethasone dipropionate on bronchial hyperreactivity in asthmatic children during maximal allergen exposure. Pediatr Pulmonol 1991; 10:2–5.
   PubMed Web of Science ®Google Scholar
• Benito-Fernández J, Onis-González E, Alvarez-Pitti J, Capapé-Zache S, Vázquez-Ronco MA, Mintegi-Raso S. Factors associated with short-term clinical outcomes after acute treatment of asthma in a pediatric emergency department. Pediatr Pulmonol 2004; 38:123–128.
   PubMed Web of Science ®Google Scholar
• Kattan M, Mitchell H, Eggleston P, Gergen P, Crain E, Redline S, Weiss K, Evans R 3rd, Kaslow R, Kercsmar C, Leickly F, Malveaux F, Wedner HJ. Characteristics of inner-city children with asthma: The national cooperative inner-citystudy. Pediatr Pulmonol 1997; 24:253–262.
   PubMed Web of Science ®Google Scholar
• Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005; (1), Art. No. CD002738. DOI: 10.1002/14651858. CD002738.pub2.
   Google Scholar
• Adams N, Bestall J, Jones PW. Budesonide versus placebo for chronic asthma in children and adults. Cochrane Database Syst Rev 1999; (4), Art No. CD003274 DOI: 10.1002/14651858.CD003274.
   Google Scholar
• Adams NP, Bestall JC, Lasserson TJ, Jones PW. Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2005 (4), Art. No. CD003135. DOI: 10.1002/14651858.CD003135.pub3.
   Google Scholar
• Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008 (2), Art. No. CD006217. DOI: 10.1002/14651858. CD006217.pub2.
   Google Scholar
• Pedersen S, Garcia Garcia ML, Manjra AL, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160mcg/day and fluticasone propionate 176 mcg/day in children with asthma. Pediatr Pulmonol 2006; 41:954–961.
   PubMed Web of Science ®Google Scholar
• Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200mcg/day with inhaled beclomethasone dipropionate 400mcg/day in mild and moderate asthma. Arch Dis Child 1993; 69:206–211.
   PubMed Web of Science ®Google Scholar
• Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Van Essen-Zandvliet E, Arora S, Szefler SJ; Pediatric Study Group. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: An open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 2002; 109:e92.
   PubMed Web of Science ®Google Scholar
• Springer C, Avital A, Maayan CH, Rosler A, Godfrey S. Comparison of budesonide and beclomethasone dipropionate for treatment of asthma. Arch Dis Child 1987; 62:815–819.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Warner J, Staab D, Wahn U, Le Bourgeois M, van Essen-Zandvliet EE, Arora S, Pedersen S; Pediatric Study Group. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: A 6-month, open-label randomized trial. J Allergy Clin Immunol 2002; 110:45–50.
   PubMed Web of Science ®Google Scholar
• Yiallourous PK, Milner AD, Conway E, Honour JH. Adrenal function and high dose inhaled corticosteroids for asthma. Arch Dis Child 1997; 76:405–410.
   PubMed Web of Science ®Google Scholar
• Francis RS. Long-term beclomethasone dipropionate aerosol therapy in juvenile asthma. Thorax 1976; 31:309–314.
   PubMed Web of Science ®Google Scholar
• Varsano I, Volovitz B, Malik H, Amir Y. Safety of 1 year of treatment with budesonide in young children with asthma. J Allergy Clin Immunol 1990; 85:914–920.
   PubMed Web of Science ®Google Scholar
• Vermeulen JH, Gyurkovits K, Rauer H, Engelstatter R. Randomized comparison and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med 2007; 101:2182–2191.
   PubMed Web of Science ®Google Scholar
• von Berg A, Engelstätter R, Minic P, Sréckovic M, Garcia Garcia ML, Latoś T, Vermeulen JH, Leichtl S, Hellbardt S, Bethke TD. Comparison of the efficacy and safety of ciclesonide 160mcg once daily vs. budesonide 400mcg once daily in children with asthma. Pediatr Allergy Immunol 2007; 18:391–400.
   PubMed Web of Science ®Google Scholar
• Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6 to 14-year-old patients with mild asthma: The MOSAIC study. Pediatrics 2005; 116:360–369.
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modeling for health economic evaluation. New York: Oxford University Press, 2006.
   Google Scholar
• Chiou CF, Weaver MR, Bell MA, Lee TA, Krieger JW. Development of the multi-atribute pediatric asthma health outcome measure (PAHOM). Int J Qual Health Care 2005; 17:23–30.
   PubMed Web of Science ®Google Scholar
• Catálogo Farmacéutico Nacional. Available at: http://www.medicentro.com.co/CATALOGO-FARMA.htm. Accessed September 17, 2012.
   Google Scholar
• British Guideline on the Management of Asthma. A national clinical guideline. British Thoracic Society. Scottish Intercollegiate Guidelines Network. Available at: http://www.sign.ac.uk/pdf/sign101.pdf. Accessed September 17, 2012.
   Google Scholar
• Banco de la República, Colombia. Series estadísticas. Tasa de cambio. Santa Fe de Bogotá: Banco de la República; 2009. Available at: http://www.banrep.gov.co/series-estadisticas/see_ts_cam.htm. Accessed September 17, 2012.
   Google Scholar
• O’Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32:150–163.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Goeree R, Blackhouse G, O’Brien B. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22:290–308.
   PubMed Web of Science ®Google Scholar
• Commission on Macroeconomics and Health, World Health Organization (WHO). Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization, 2001.
   Google Scholar
• Acceso a medicamentos esenciales: compras corporativas nacionales y implicancias para el nivel regional y local. Available at: http://www.eurosocialsalud.eu/files/docs/00064.pdf. Accessed September 17, 2012.
   Google Scholar
• Adams N, Lasserson TJ, Cates CJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007 (4), Art. No. CD002310. DOI: 10.1002/14651858.CD002310.pub4.
   Google Scholar
• Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database Syst Rev 2008 (2), Art. No. CD007031. DOI: 10.1002/14651858.CD007031.
   Google Scholar
• Sabin T, Gurumurthy P, Shilpa P, Jayaraj BS, Basavana Gowda H, Mahesh PA. Quality of life assessment in asthmatic patients receiving fluticasone compared with equipotent doses of beclomethasone or budesonide. Lung India 2005; 22:86–91.
   Google Scholar
• Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998; 102:36–51.
   PubMed Web of Science ®Google Scholar
• Phillips GH. Structure-activity relationships of topically active steroids: The selection of fluticasone propionate. Respir Med 1990; 84(Suppl A):19–23.
   PubMed Web of Science ®Google Scholar
• Shaw RJ. Inhaled corticosteroids for adult asthma: Impact of formulation and delivery device on relative pharmacokinetics, efficacy and safety. Respir Med 1999; 93:149–160.
   PubMed Web of Science ®Google Scholar
• Anselmo M. Pediatric asthma controller therapy. Paediatr Drugs 2011; 13:11–17.
   PubMed Web of Science ®Google Scholar
• Allen DB. Safety of inhaled corticosteroids in children. Pediatr Pulmonol 2002; 33:208–220.
   PubMed Web of Science ®Google Scholar
• Kelly HW, Sternberg AL, Lescher R. Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC; CAMP Research Group. Effects of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367:904–912.
   PubMed Web of Science ®Google Scholar
• Barnes NC, Thwaites RMA, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med 1999; 93:402–407.
   PubMed Web of Science ®Google Scholar
• Trakas K, Oh PI, Einarson TR, Shear NH. A health economic analysis of fluticasone propionate, budesonide, and beclomethasone dipropionate for the treatment of moderate to severe asthma. Value Health 1998; 1:62.
   Google Scholar
• Neumann PJ. What next for QALYs? J Am Med Assoc 2011; 305:1806–1807.
   PubMed Web of Science ®Google Scholar
• UK Secretary of State for Health Department of Health. A new value-based approach to the pricing of branded medicines-a consultation. Available at: http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_122760. Accessed September 17, 2012.
   Google Scholar